- Bruker Corp‘s preliminary adjusted earnings per share (EPS) for the second quarter of 2025 are estimated to be between 32 cents and 34 cents, below the expected 42 cents.
- Preliminary revenue for the same period is projected to be between $795 million and $798 million, short of the $813 million estimate.
- The company’s second-quarter bookings have been affected by weak demand in the academic sector and a softer U.S. biopharma market.
- Bruker shares decreased by 3.8% in pre-market trading, reaching $39.00 with 2,378 shares traded.
- The stock is currently rated with 7 buy recommendations, 6 hold, and 1 sell.
- Bruker plans to discuss its second-quarter financial results, business developments, and ongoing cost actions in a conference call scheduled for August 4, 2025, at 8:30 a.m. EDT.
A look at Bruker Corp Smart Scores
| Factor | Score | Magnitude |
|---|---|---|
| Value | 3 | |
| Dividend | 2 | |
| Growth | 2 | |
| Resilience | 2 | |
| Momentum | 3 | |
| OVERALL SMART SCORE | 2.4 |
Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma
Based on the Smartkarma Smart Scores, Bruker Corp is positioned with moderate scores across key factors. With a Value score of 3, the company seems to offer reasonable value based on its price compared to fundamentals. However, the Dividend, Growth, Resilience, and Momentum scores all hover around the mid-range, indicating mixed performance in these areas. This suggests that while Bruker Corp may not be strongly excelling in any specific aspect, it also does not exhibit significant weaknesses.
Bruker Corporation specializes in designing and manufacturing life science systems utilizing spectrometry technology platforms. Additionally, the company markets field analytical systems for substance detection and pathogen identification. Known for developing research tools based on X-ray technology, Bruker Corp seems to operate in a niche market with a focus on innovative technologies for various scientific applications.
Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Analytics and News
- ✓ Events & Webinars
